COMMUNIQUÉS West-GlobeNewswire

Orion Group Interim report January–March 2026
23/04/2026
ORION CORPORATION INTERIM REPORT 1–3/2026 23 APRIL 2026 at 12:00 EEST Orion Group Interim report January–March 2026 January–March 2026 Highlights Net sales totalled EUR 417.7 (January–March 2025: 354.6) million [...]
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
23/04/2026
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing [...]
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
23/04/2026
Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno [...]
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
23/04/2026
Total sales growth of 22.6% at CER 1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline ® , growing by 27.5% at CER Strong pipeline momentum with three [...]
Santhera Appoints Orlando Oliveira as Chief Executive Officer
23/04/2026
Ad hoc announcement pursuant to Art. 53 LR. Dario Eklund to hand over leadership following planned transition Pratteln, Switzerland, April 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of [...]
Press Release: Q1 2026: double-digit sales and business EPS growth
23/04/2026
Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER 1 and business earnings per share (EPS) 2 of €1.88 Pharma launches sales increased by 49.6%, reaching €1.2 [...]
OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO
23/04/2026
Nantes, France, 23 avril 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et [...]
Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels
23/04/2026
Croissance du chiffre d’affaires total de 22,6 % à taux de change constant 1 , ou 17,0 % en données publiées, portée par les trois aires thérapeutiques, avec une accélération de la dynamique du portefeuille hors [...]
Zelluna ASA – Annual General Meeting held on April 23, 2026
23/04/2026
Oslo, April 23, 2026: Zelluna ASA held its annual general meeting on April 23, 2026. All matters on the agenda were approved. The minutes from the meeting are enclosed and are also available on the company’s website. [...]
Une découverte susceptible de valoir un prix Nobel par les scientifiques de VectorBuilder révèle les mécanismes fondamentaux du développement
23/04/2026
CHICAGO, 23 avr. 2026 (GLOBE NEWSWIRE) -- L’une des questions les plus fondamentales de la biologie est de comprendre comment un seul œuf fécondé produit la diversité des types cellulaires constituant le corps — des [...]
Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
23/04/2026
ORION CORPORATION PRESS RELEASE 23 APRIL 2026 at 09.00 EEST Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid [...]
Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA
23/04/2026
T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA Paris, le 23 avril 2026 Ventes du T1 en progression de 13,6 % à TCC 1 et BNPA 2 des activités de 1,88 euro Les ventes des nouveaux lancements Pharma [...]
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
23/04/2026
Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the [...]
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
23/04/2026
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at ERA 2025, ASN [...]
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
23/04/2026
-Results to be presented at ARVO 2026 Annual Meeting- PARIS, April 23, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene [...]
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
23/04/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
23/04/2026
Group sales were +6% at constant exchange rates (CER) 1 , -5% when reported in CHF and +9% in USD 2 , in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmaceuticals [...]
New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources
23/04/2026
COPENHAGEN, Denmark, April 23, 2026 (GLOBE NEWSWIRE) -- The Novo Nordisk Foundation Challenge Programme supports development of new knowledge to help tackle major societal challenges within human and planetary health. [...]
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
23/04/2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing [...]

Pages